An alternative approach identified optimal risk thresholds for treatment indication: an illustration in coronary heart disease

被引:2
作者
van Giessen, Anoukh [1 ]
de Wit, G. Ardine [1 ,2 ]
Moons, Karel G. M. [1 ]
Dorresteijn, Jannick A. N. [3 ]
Koffijberg, Hendrik [1 ,4 ]
机构
[1] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, POB 85500,STRAT 6-131, NL-3508 GA Utrecht, Netherlands
[2] Natl Inst Publ Hlth & Environm, POB 1, NL-3720 BA Bilthoven, Netherlands
[3] Univ Med Ctr Utrecht, Dept Vasc Med, POB 85500,F02-126, NL-3508 GA Utrecht, Netherlands
[4] Univ Twente, Dept Hlth Technol & Serv Res, MIRA Inst, POB 217, NL-7500 AE Enschede, Netherlands
关键词
Treatment threshold; Risk stratification; Coronary heart disease; Marginal analysis; Cost-effectiveness; Optimization; LOW-CARDIOVASCULAR-RISK; COST-EFFECTIVENESS; PRIMARY PREVENTION; CLINICAL-PRACTICE; HEALTH-BENEFITS; STATIN THERAPY; 10-YEAR RISK; PREDICTION; PEOPLE; CHOLESTEROL;
D O I
10.1016/j.jclinepi.2017.09.020
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: Treatment thresholds based on risk predictions can be optimized by considering various health (economic) outcomes and performing marginal analyses, but this is rarely performed. We demonstrate a general approach to identify treatment thresholds optimizing individual health (economic) outcomes, illustrated for statin treatment based on 10-year coronary heart disease (CHD) risk predicted by the Framingham risk score. Study Design and Setting: Creating a health economic model for a risk-based prevention strategy, risk thresholds can be evaluated on several outcomes of interest. Selecting an appropriate threshold range and decrement size for the thresholds and adapting the health economic model accordingly, outcomes can be calculated for each risk threshold. A stepwise, or marginal, comparison of clinical as well as health economic outcomes, that is, comparing outcomes using a specific threshold to outcomes of the former threshold while gradually lowering the threshold, then takes into account the balance between additional numbers of individuals treated and their outcomes (additional health effects and costs). In our illustration, using a Markov model for CHD, we evaluated risk thresholds by gradually lowering thresholds from 20% to 0%. Results: This approach can be applied to identify optimal risk thresholds on any outcome, such as to limit complications, maximize health outcomes, or optimize cost-effectiveness. In our illustration, keeping the population-level fraction of statin-induced complications <10% resulted in thresholds of T = 6% (men) and T = 2% (women). Lowering the threshold and comparing quality-adjusted life-years (QALYs) after each 1% decrease, QALYs were gained down to T = 1% (men) and T = 0% (women). Also accounting for costs, net health benefits were favorable down to T = 3% (men) and T = 6% (women). Conclusion: Using a stepwise risk-based approach to threshold optimization allows for preventive strategies that optimize outcomes. Presenting this comprehensive overview of outcomes will better inform decision makers when defining a treatment threshold. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:122 / 131
页数:10
相关论文
共 42 条
  • [1] Should people at low risk of cardiovascular disease take a statin?
    Abramson, John D.
    Rosenberg, Harriet G.
    Jewell, Nicholas
    Wright, James M.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2013, 347
  • [2] At what hip fracture risk is it cost-effective to treat?: International intervention thresholds for the treatment of osteoporosis
    Borgstroem, F.
    Johnell, O.
    Kanis, J. A.
    Joensson, B.
    Rehnberg, C.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 (10) : 1459 - 1471
  • [3] Briggs A., 2006, Decision modelling for health economic evaluation
  • [4] What Is the Optimal Threshold at Which to Recommend Breast Biopsy?
    Burnside, Elizabeth S.
    Chhatwal, Jagpreet
    Alagoz, Oguzhan
    [J]. PLOS ONE, 2012, 7 (11):
  • [5] Buxton MJ, 1997, HEALTH ECON, V6, P217, DOI 10.1002/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.0.CO
  • [6] 2-W
  • [7] Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study
    Chambless, LE
    Folsom, AR
    Sharrett, AR
    Sorlie, P
    Couper, D
    Szklo, M
    Nieto, FJ
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2003, 56 (09) : 880 - 890
  • [8] Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction medicare beneficiaries
    Choudhry, Niteesh K.
    Patrick, Amanda R.
    Antman, Elliott M.
    Avorn, Jerry
    Shrank, William H.
    [J]. CIRCULATION, 2008, 117 (10) : 1261 - 1268
  • [9] Estimation of ten-year risk of fatal cardiovascular disease in Europe:: the SCORE project
    Conroy, RM
    Pyörälä, K
    Fitzgerald, AP
    Sans, S
    Menotti, A
    De Backer, G
    De Bacquer, D
    Ducimetière, P
    Jousilahti, P
    Keil, U
    Njolstad, I
    Oganov, RG
    Thomsen, T
    Tunstall-Pedoe, H
    Tverdal, A
    Wedel, H
    Whincup, P
    Wilhelmsen, L
    Graham, IM
    [J]. EUROPEAN HEART JOURNAL, 2003, 24 (11) : 987 - 1003
  • [10] Long-term health benefits and costs of measurement of carotid intima-media thickness in prevention of coronary heart disease
    den Ruijter, Hester M.
    Vaartjes, Ilonca
    Sutton-Tyrrell, Kim
    Bots, Michiel L.
    Koffijberg, Hendrik
    [J]. JOURNAL OF HYPERTENSION, 2013, 31 (04) : 782 - 790